APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Fidaxomicin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Fidaxomicin Market Outlook and Growth Opportunities 2026

27 December 2025198 pages

Choose your research edition.

Industry ResearchFidaxomicin Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Fidaxomicin Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Fidaxomicin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Fidaxomicin Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Fidaxomicin Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Fidaxomicin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Fidaxomicin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Fidaxomicin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Fidaxomicin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Fidaxomicin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Fidaxomicin market include Merck, Livzon Group, Tecoland, Rochem, Optimer Pharmaceuticals, Olon, BrightGene Bio-Medical Technology and Astellas, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Fidaxomicin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Fidaxomicin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Fidaxomicin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Fidaxomicin market size, projected growth trends, production technologies, key applications, and end-use industries.

Fidaxomicin Segment by Company

Merck

Livzon Group

Tecoland

Rochem

Optimer Pharmaceuticals

Olon

BrightGene Bio-Medical Technology

Astellas

Fidaxomicin Segment by Type

Purity:90%

Purity:95%

Others

Fidaxomicin Segment by Application

Hospital

Retail Pharmacies

Fidaxomicin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Fidaxomicin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Fidaxomicin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Fidaxomicin significant trends, drivers, influence factors in global and regions.

6. To analyze Fidaxomicin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fidaxomicin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Fidaxomicin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fidaxomicin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Fidaxomicin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Fidaxomicin industry.

Chapter 3: Detailed analysis of Fidaxomicin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Fidaxomicin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Fidaxomicin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Fidaxomicin Industry Trends Table 2. Fidaxomicin Industry Drivers Table 3. Fidaxomicin Industry Opportunities and Challenges Table 4. Fidaxomicin Industry Restraints Table 5. Global Fidaxomicin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Fidaxomicin Revenue Share by Company (2021-2026) Table 7. Global Fidaxomicin Sales Volume by Company (W Pcs) & (2021-2026) Table 8. Global Fidaxomicin Sales Volume Share by Company (2021-2026) Table 9. Global Fidaxomicin Average Price (US$/Pcs) of Company (2021-2026) Table 10. Global Fidaxomicin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Fidaxomicin Key Company Manufacturing Base & Headquarters Table 12. Global Fidaxomicin Company, Product Type & Application Table 13. Global Fidaxomicin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Fidaxomicin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Purity:90% Table 18. Significant Companies of Purity:95% Table 19. Significant Companies of Others Table 20. Global Fidaxomicin Sales Volume by Type 2021 VS 2025 VS 2032 (W Pcs) Table 21. Global Fidaxomicin Sales Volume by Type (2021-2026) & (W Pcs) Table 22. Global Fidaxomicin Sales Volume by Type (2027-2032) & (W Pcs) Table 23. Global Fidaxomicin Sales Volume Share by Type (2021-2026) Table 24. Global Fidaxomicin Sales Volume Share by Type (2027-2032) Table 25. Global Fidaxomicin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Fidaxomicin Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Fidaxomicin Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Fidaxomicin Sales Value Share by Type (2021-2026) Table 29. Global Fidaxomicin Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Retail Pharmacies Table 32. Global Fidaxomicin Sales Volume by Application 2021 VS 2025 VS 2032 (W Pcs) Table 33. Global Fidaxomicin Sales Volume by Application (2021-2026) & (W Pcs) Table 34. Global Fidaxomicin Sales Volume by Application (2027-2032) & (W Pcs) Table 35. Global Fidaxomicin Sales Volume Share by Application (2021-2026) Table 36. Global Fidaxomicin Sales Volume Share by Application (2027-2032) Table 37. Global Fidaxomicin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Fidaxomicin Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Fidaxomicin Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Fidaxomicin Sales Value Share by Application (2021-2026) Table 41. Global Fidaxomicin Sales Value Share by Application (2027-2032) Table 42. Global Fidaxomicin Sales by Region: 2021 VS 2025 VS 2032 (W Pcs) Table 43. Global Fidaxomicin Sales by Region (2021-2026) & (W Pcs) Table 44. Global Fidaxomicin Sales Market Share by Region (2021-2026) Table 45. Global Fidaxomicin Sales by Region (2027-2032) & (W Pcs) Table 46. Global Fidaxomicin Sales Market Share by Region (2027-2032) Table 47. Global Fidaxomicin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Fidaxomicin Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Fidaxomicin Sales Value Share by Region (2021-2026) Table 50. Global Fidaxomicin Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Fidaxomicin Sales Value Share by Region (2027-2032) Table 52. Global Fidaxomicin Market Average Price (US$/Pcs) by Region (2021-2026) Table 53. Global Fidaxomicin Market Average Price (US$/Pcs) by Region (2027-2032) Table 54. Global Fidaxomicin Sales by Country: 2021 VS 2025 VS 2032 (W Pcs) Table 55. Global Fidaxomicin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Fidaxomicin Sales by Country (2021-2026) & (W Pcs) Table 57. Global Fidaxomicin Sales Market Share by Country (2021-2026) Table 58. Global Fidaxomicin Sales by Country (2027-2032) & (W Pcs) Table 59. Global Fidaxomicin Sales Market Share by Country (2027-2032) Table 60. Global Fidaxomicin Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Fidaxomicin Sales Value Market Share by Country (2021-2026) Table 62. Global Fidaxomicin Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Fidaxomicin Sales Value Market Share by Country (2027-2032) Table 64. Merck Company Information Table 65. Merck Business Overview Table 66. Merck Fidaxomicin Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 67. Merck Fidaxomicin Product Portfolio Table 68. Merck Recent Development Table 69. Livzon Group Company Information Table 70. Livzon Group Business Overview Table 71. Livzon Group Fidaxomicin Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 72. Livzon Group Fidaxomicin Product Portfolio Table 73. Livzon Group Recent Development Table 74. Tecoland Company Information Table 75. Tecoland Business Overview Table 76. Tecoland Fidaxomicin Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 77. Tecoland Fidaxomicin Product Portfolio Table 78. Tecoland Recent Development Table 79. Rochem Company Information Table 80. Rochem Business Overview Table 81. Rochem Fidaxomicin Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 82. Rochem Fidaxomicin Product Portfolio Table 83. Rochem Recent Development Table 84. Optimer Pharmaceuticals Company Information Table 85. Optimer Pharmaceuticals Business Overview Table 86. Optimer Pharmaceuticals Fidaxomicin Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 87. Optimer Pharmaceuticals Fidaxomicin Product Portfolio Table 88. Optimer Pharmaceuticals Recent Development Table 89. Olon Company Information Table 90. Olon Business Overview Table 91. Olon Fidaxomicin Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 92. Olon Fidaxomicin Product Portfolio Table 93. Olon Recent Development Table 94. BrightGene Bio-Medical Technology Company Information Table 95. BrightGene Bio-Medical Technology Business Overview Table 96. BrightGene Bio-Medical Technology Fidaxomicin Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 97. BrightGene Bio-Medical Technology Fidaxomicin Product Portfolio Table 98. BrightGene Bio-Medical Technology Recent Development Table 99. Astellas Company Information Table 100. Astellas Business Overview Table 101. Astellas Fidaxomicin Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 102. Astellas Fidaxomicin Product Portfolio Table 103. Astellas Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Fidaxomicin Distributors List Table 107. Fidaxomicin Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Fidaxomicin Product Image Figure 2. Global Fidaxomicin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Fidaxomicin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Fidaxomicin Sales (2021-2032) & (W Pcs) Figure 5. Global Fidaxomicin Sales Average Price (US$/Pcs) & (2021-2032) Figure 6. Global Fidaxomicin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Purity:90% Image Figure 10. Purity:95% Image Figure 11. Others Image Figure 12. Global Fidaxomicin Sales Volume by Type (2021 VS 2025 VS 2032) & (W Pcs) Figure 13. Global Fidaxomicin Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Fidaxomicin Sales Volume Share by Type (2021-2032) Figure 15. Global Fidaxomicin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Fidaxomicin Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Fidaxomicin Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Retail Pharmacies Image Figure 20. Global Fidaxomicin Sales Volume by Application (2021 VS 2025 VS 2032) & (W Pcs) Figure 21. Global Fidaxomicin Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Fidaxomicin Sales Volume Share by Application (2021-2032) Figure 23. Global Fidaxomicin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Fidaxomicin Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Fidaxomicin Sales Value Share by Application (2021-2032) Figure 26. Global Fidaxomicin Sales by Region: 2021 VS 2025 VS 2032 (W Pcs) Figure 27. Global Fidaxomicin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Fidaxomicin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Fidaxomicin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Fidaxomicin Sales Value (2021-2032) & (US$ Million) Figure 31. North America Fidaxomicin Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Fidaxomicin Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Fidaxomicin Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Fidaxomicin Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Fidaxomicin Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Fidaxomicin Sales Value (2021-2032) & (US$ Million) Figure 37. South America Fidaxomicin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Fidaxomicin Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Fidaxomicin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Fidaxomicin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Fidaxomicin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Fidaxomicin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Fidaxomicin Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Fidaxomicin Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Purity:90%
  • Purity:95%
  • Others
Applications
  • Hospital
  • Retail Pharmacies
Companies covered
  • Merck
  • Livzon Group
  • Tecoland
  • Rochem
  • Optimer Pharmaceuticals
  • Olon
  • BrightGene Bio-Medical Technology
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Fidaxomicin Sales Value (2021-2032)
  4. 1.2.2 Global Fidaxomicin Sales Volume (2021-2032)
  5. 1.2.3 Global Fidaxomicin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Fidaxomicin Market Dynamics
  1. 2.1 Fidaxomicin Industry Trends
  2. 2.2 Fidaxomicin Industry Drivers
  3. 2.3 Fidaxomicin Industry Opportunities and Challenges
  4. 2.4 Fidaxomicin Industry Restraints
3 Fidaxomicin Market by Company
  1. 3.1 Global Fidaxomicin Company Revenue Ranking in 2025
  2. 3.2 Global Fidaxomicin Revenue by Company (2021-2026)
  3. 3.3 Global Fidaxomicin Sales Volume by Company (2021-2026)
  4. 3.4 Global Fidaxomicin Average Price by Company (2021-2026)
  5. 3.5 Global Fidaxomicin Company Ranking (2024-2026)
  6. 3.6 Global Fidaxomicin Company Manufacturing Base and Headquarters
  7. 3.7 Global Fidaxomicin Company Product Type and Application
  8. 3.8 Global Fidaxomicin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Fidaxomicin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Fidaxomicin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Fidaxomicin Market by Type
  1. 4.1 Fidaxomicin Type Introduction
  2. 4.1.1 Purity:90%
  3. 4.1.2 Purity:95%
  4. 4.1.3 Others
  5. 4.2 Global Fidaxomicin Sales Volume by Type
  6. 4.2.1 Global Fidaxomicin Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Fidaxomicin Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Fidaxomicin Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Fidaxomicin Sales Value by Type
  10. 4.3.1 Global Fidaxomicin Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Fidaxomicin Sales Value by Type (2021-2032)
  12. 4.3.3 Global Fidaxomicin Sales Value Share by Type (2021-2032)
5 Fidaxomicin Market by Application
  1. 5.1 Fidaxomicin Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacies
  4. 5.2 Global Fidaxomicin Sales Volume by Application
  5. 5.2.1 Global Fidaxomicin Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Fidaxomicin Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Fidaxomicin Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Fidaxomicin Sales Value by Application
  9. 5.3.1 Global Fidaxomicin Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Fidaxomicin Sales Value by Application (2021-2032)
  11. 5.3.3 Global Fidaxomicin Sales Value Share by Application (2021-2032)
6 Fidaxomicin Regional Sales and Value Analysis
  1. 6.1 Global Fidaxomicin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Fidaxomicin Sales by Region (2021-2032)
  3. 6.2.1 Global Fidaxomicin Sales by Region: 2021-2026
  4. 6.2.2 Global Fidaxomicin Sales by Region (2027-2032)
  5. 6.3 Global Fidaxomicin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Fidaxomicin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Fidaxomicin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Fidaxomicin Sales Value by Region (2027-2032)
  9. 6.5 Global Fidaxomicin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Fidaxomicin Sales Value (2021-2032)
  12. 6.6.2 North America Fidaxomicin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Fidaxomicin Sales Value (2021-2032)
  15. 6.7.2 Europe Fidaxomicin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Fidaxomicin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Fidaxomicin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Fidaxomicin Sales Value (2021-2032)
  21. 6.9.2 South America Fidaxomicin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Fidaxomicin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Fidaxomicin Sales Value Share by Country, 2025 VS 2032
7 Fidaxomicin Country-level Sales and Value Analysis
  1. 7.1 Global Fidaxomicin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Fidaxomicin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Fidaxomicin Sales by Country (2021-2032)
  4. 7.3.1 Global Fidaxomicin Sales by Country (2021-2026)
  5. 7.3.2 Global Fidaxomicin Sales by Country (2027-2032)
  6. 7.4 Global Fidaxomicin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Fidaxomicin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Fidaxomicin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Fidaxomicin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Fidaxomicin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Fidaxomicin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Fidaxomicin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Fidaxomicin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Fidaxomicin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Fidaxomicin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Fidaxomicin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Fidaxomicin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Fidaxomicin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Fidaxomicin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Fidaxomicin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Fidaxomicin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Fidaxomicin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Fidaxomicin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Fidaxomicin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Fidaxomicin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Fidaxomicin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Fidaxomicin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Fidaxomicin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Fidaxomicin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Fidaxomicin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Fidaxomicin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Fidaxomicin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Fidaxomicin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Fidaxomicin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Fidaxomicin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Fidaxomicin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Fidaxomicin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Fidaxomicin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Fidaxomicin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Fidaxomicin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Fidaxomicin Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Livzon Group
  8. 8.2.1 Livzon Group Company Information
  9. 8.2.2 Livzon Group Business Overview
  10. 8.2.3 Livzon Group Fidaxomicin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Livzon Group Fidaxomicin Product Portfolio
  12. 8.2.5 Livzon Group Recent Developments
  13. 8.3 Tecoland
  14. 8.3.1 Tecoland Company Information
  15. 8.3.2 Tecoland Business Overview
  16. 8.3.3 Tecoland Fidaxomicin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Tecoland Fidaxomicin Product Portfolio
  18. 8.3.5 Tecoland Recent Developments
  19. 8.4 Rochem
  20. 8.4.1 Rochem Company Information
  21. 8.4.2 Rochem Business Overview
  22. 8.4.3 Rochem Fidaxomicin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Rochem Fidaxomicin Product Portfolio
  24. 8.4.5 Rochem Recent Developments
  25. 8.5 Optimer Pharmaceuticals
  26. 8.5.1 Optimer Pharmaceuticals Company Information
  27. 8.5.2 Optimer Pharmaceuticals Business Overview
  28. 8.5.3 Optimer Pharmaceuticals Fidaxomicin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Optimer Pharmaceuticals Fidaxomicin Product Portfolio
  30. 8.5.5 Optimer Pharmaceuticals Recent Developments
  31. 8.6 Olon
  32. 8.6.1 Olon Company Information
  33. 8.6.2 Olon Business Overview
  34. 8.6.3 Olon Fidaxomicin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Olon Fidaxomicin Product Portfolio
  36. 8.6.5 Olon Recent Developments
  37. 8.7 BrightGene Bio-Medical Technology
  38. 8.7.1 BrightGene Bio-Medical Technology Company Information
  39. 8.7.2 BrightGene Bio-Medical Technology Business Overview
  40. 8.7.3 BrightGene Bio-Medical Technology Fidaxomicin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 BrightGene Bio-Medical Technology Fidaxomicin Product Portfolio
  42. 8.7.5 BrightGene Bio-Medical Technology Recent Developments
  43. 8.8 Astellas
  44. 8.8.1 Astellas Company Information
  45. 8.8.2 Astellas Business Overview
  46. 8.8.3 Astellas Fidaxomicin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Astellas Fidaxomicin Product Portfolio
  48. 8.8.5 Astellas Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Fidaxomicin Value Chain Analysis
  2. 9.1.1 Fidaxomicin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Fidaxomicin Sales Mode & Process
  6. 9.2 Fidaxomicin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Fidaxomicin Distributors
  9. 9.2.3 Fidaxomicin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst